New Data Show Statistically Significant Reduction in Chronic Cancer-Related Lymphedema with Early Detection Using ImpediMed’s L-Dex® Technology and Intervention
CARLSBAD, Calif., and BRISBANE, Australia, Feb. 1, 2022 /PRNewswire/ -- ImpediMed Limited (ASX: IPD), a global medical technology company using...